ACT BlackRock Inc., Fmr Llc, Vanguard Group Inc, State Street Corp, Brown Capital Management Llc, and Janus Capital Management Llc. IRWDV ALPMY Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) along with partner Allergan (AGN - Free Report) announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). PFE BZMD, 2019-10-03 seekingalpha.com - 14 BZH IRWD IRWDV, 2019-07-31 seekingalpha.com A question-and-answer session will follow the formal presentation. IMPHP September 30, 2020. ALPMF. At this time, all participants are in a listen-only mode. )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, 2019-02-14 sec.gov Boxer Capital, LLC, Sandell Asset Management Corp, Franklin Resources Inc, Bank Of America Corp /de/, and Guggenheim Capital Llc. the table as changes in names and CUSIPs. Nothing on this website constitutes, or is meant to constitute, advice of any kind. Medicines Co. (MDCO - Free Report) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.66. )* Ironwood Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 46333X108 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 0683. All rights reserved. MDCO, 2019-05-25 zacks.com IRWD ALNY, 2019-10-30 seekingalpha.com SBNA Stay ahead of the market with real-time insider trading alerts. Activist Profiles. PFIZER, 2019-06-19 malaymail.com Shares have added about 6.9% in that time frame, outperforming the S&P 500. This represents 0.0 percent ownership of the company. MDCO. Information includes fund holdings, fund sentiment, financial data, and regulatory filings (including SEC, LSE, ASX, and SGX). The Montier C-score has been added to the models of Beneish, Altman, and Ohlson to detect earnings manipulation, financial irregularities, bankruptcy risk, and corporate distress. are not directly comparable to any numbers shown in the 13F table (if any). Note that the share values in this table It has been about a month since the last earnings report for Medicines Co. (MDCO - Free Report) . PFZ IRWD The S&P 500 approached a record high on Wednesday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the U.S.-China trade war could stall economic growth. Sarissa focuses on improving the strategies of health-care companies to enhance shareholder value. Spokespersons from neither Novartis nor Medicines could immediately be reached for comment. - Ironwood Pharmaceuticals, headquartered in Cambridge, Mass., and Allergan, headquartered in Dublin, Ireland, announced positive topline data from their Phase IIIb clinical trial of Linzess (linaclotide) in irritable bowel syndrome. In 2013 he founded Sarissa Capital Management LP, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the health-care sector. - (Reuters) - Wall Street’s main indexes took a pause on Wednesday, after a rally the previous day, as investors held back from making big bets ahead of the Federal Reserve’s policy statement that is expected to lay the groundwork for future interest rate cuts. Wall Street Baffled Why Activist Sarissa Went Silent on Ironwood By . In their previous filing dated May 30, 2019, Sarissa Capital Management LP had reported owning 4,152,000 shares, 2019-06-10 sec.gov - 1 MDCO January 07, 2020 In addition to descriptive data, performance of the investment NOTE - 0.75% 2024-06-15, 46333XAE8 / CONV. )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, 2019-11-19 marketwatch.com ALNY, 2019-09-03 marketwatch.com - 1 IRWDV PFZ Sarissa Capital. STNG 2019-05-30 sec.gov - 8 JLH AXR IMH TWST Upgrade to unlock premium data and export to Excel . 500680 See our Privacy Policy and Terms and Conditions. At this time, all participants are in a listen-only mode. 2019-09-09 sec.gov - It has been about a month since the last earnings report for Medicines Co. (MDCO - Free Report) . Spokespersons from neither Novartis nor Medicines could immediately be reached for comment. Activist hedge fund Sarissa Capital's healthcare SPAC Sarissa Capital Acquisition files for a $175 million IPO. AGN For investment firms, these © 2015-2020 Fintel Ventures LLC. Nothing on this website constitutes, or is meant to constitute, advice of any kind. This table shows a history of the 13D/G filings made by the investor and/or investor group. TATE : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file, 2019-05-16 sec.gov - 4 IRWDV that to calculate gross profit. TORONTO, June 20 — The S&P 500 approached a record high yesterday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings. Prior to founding Sarissa, Dr. Denner was the healthcare portfolio manager of Icahn Capital. - (For a live blog on the U.S. stock market, click or type LIVE/ in a news window) MDCO, 2019-07-24 zacks.com MTH Recent examples include representing: ARIAD Pharmaceuticals in the adoption of its shareholder rights plan and in its settlement agreement with Sarissa Capital; Sarissa Capital Management LP discloses 7.90% activist ownership in IRWD / Ironwood Pharmaceuticals, Inc. February 26, 2020 - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 12,493,000 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD). 500680 Need help or want to help improve Fintel? TJX HD AQST In addition to descriptive data, performance of the investment MDCO Message Board data supplied by SiliconInvestor . IRWDV, 2019-06-20 moneycontrol.com Real-time pricing data supplied by IEX. indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. AGN IRWD Sarissa Capital Management is a Greenwich, Connecticut-based activist hedge fund established in 2012 by its current chief investment officer, Dr. Alexander John Denner, also known as Alex PhD. 0 13F Universe (Hedge Fund Holdings Tracker), 46333XAF5 / CONV. - Greetings, welcome to The Medicines Company Third Quarter 2019 Earnings Call Webcast. UNH - Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.61% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs. NEW YORK -- Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.Sarissa, led by … - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ACT Represented Sarissa Capital Management in connection with its proxy contest for representation the board of directors of Ironwood Pharmaceuticals, resulting in a spin-off of its R&D business. Denner has orchestrated the sale of companies such as Bioverativ and Ariad Pharmaceuticals. PFIZER, 2019-06-01 zacks.com IRWD IRWDV Tatiana Darie ... annual meeting and Sarissa Capital Management has yet to … Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings. Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning … The activist hedge fund indicated its intention to engage in discussions with the leadership of the company regarding its investment. Quarterly return is Gross Profit / Starting Portfolio value. The Medicines Co. stock MDCO, +13.51% was reiterated as a Top Pick for 2019 at Chardan on Tuesday, with analyst Gbola Amusa highlighting the positive results from a late-stage trial of a treatment for cholesterol. Improve your mastery of Fintel and investing by attending a webinar. Ladies and gentlemen, thank you for standing-by and welcome to the Alnylam Pharmaceuticals Conference Call Third Quarter Earnings. This website is provided “as is” without any representations or warranties, express or implied. January 07, 2020 - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Medicines Company (US:MDCO). Portfolio holdings 500680 Alex Denner Founder and CIO Sarissa Capital Management. Webinars are open )* The Medicines Company (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 584688105 (CUSIP Number) Mark DiPaolo Senior Partner, General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 (N, SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ironwood Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 46333X108 (CUSIP Number) Eddie C. The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2019 Q3 earnings call. SBBC IRWD PFE indicating a decrease of -100.00 percent. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. result in a cost basis of zero. The said a Phase 3 trial of incliran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol, or LDL-C, and the first and only cholesterol-lowering therapy Real-time pricing data supplied by IEX. IRWDV [Operator Instructions] Please be advised that this call is being taped at the company’s request. The Greenwich, CT-based company plans to raise $175 million by offering 17.5 million units at $10. UNH, 2019-06-19 biospace.com - 1 Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. - Ladies and gentlemen, thank you for standing-by and welcome to the Alnylam Pharmaceuticals Conference Call Third Quarter Earnings. - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. EAH A month has gone by since the last earnings report for Ironwood Pharmaceuticals (IRWD - Free Report) . UNH Cumulative year-to-date estimated BLM gains are now at 145.85%, by comparison with 18.98% for the S&P 500 Index. 4503 IRWDV A question-and-answer session will follow the formal presentation. Shares of Medicines Co. MDCO, +12.83% climbed 17% in premarket trading on Tuesday after a Bloomberg report that Swiss drugmaker Novartis AG NOVN, +0.61% NVS, +0.32% could be mulling an offer for the maker of cholesterol drugs. This compares to loss of $0.63 per share a year ago. Other investors with closed positions include Shares have added about 17.1% in that time frame, outperforming the S&P 500. are not directly comparable to any numbers shown in the 13F table (if any). - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. Represented Hudson’s Bay Company in the defense of several activist campaigns by Land and Buildings. SBNB - The Medicines Co. stock MDCO, +13.51% was reiterated as a Top Pick for 2019 at Chardan on Tuesday, with analyst Gbola Amusa highlighting the positive results from a late-stage trial of a treatment for cholesterol. RAD ACT Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report. CYCN, 2019-06-19 reuters.com 1)* The Medicines Company (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru, 2019-05-30 sec.gov - 4 Tracking changes used to be nearly impossible. - The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2019 Q3 earnings call. PFIZER, 2019-06-19 watoday.com.au IRWDV for registration and will fill up soon, so sign up now! 2)* Ironwood Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 46333X108 (CUSIP Number) Eddie C. 2019-10-31 seekingalpha.com is shown over time. In 2013, he founded Sarissa Capital Management LP, a registered investment advisor, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the healthcare sector. MS - Cumulative year-to-date estimated BLM gains are now at 145.85%, by comparison with 18.98% for the S&P 500 Index. At Icahn, he developed Icahn’s activist strategy in healthcare and was responsible for some of the firm’s most successful investments, including ImClone, Genzyme, Amylin, … Fintel helps you track changes to important SEC filings. Upgrade to unlock premium data and export to Excel . IRWD CVS, 2019-10-07 seekingalpha.com - 1 3)* THE MEDICINES COMPANY (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi, 2019-02-14 sec.gov - 2 If you require advice in relation to any financial matter you should consult an appropriate professional. The company is led by CEO and Chairman Alexander Denner, who … WASHINGTON, Oct 9 — GlaxoSmithKline yesterday said it is recalling the popular heartburn medicine Zantac in all markets as a “precaution,” days after the US Food and Drug Administration found “unacceptable” levels of probable cancer-causing impurity in the drug. Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. If you require advice in relation to any financial matter you should consult an appropriate professional. Just a … PNL [Operator Instructions] Please note this conference is being recorded. According to Bloomberg, Sarissa Capital will manage relatively concentrated, long-biased portfolio of healthcare investments and will typically play an activist role.. AGN IRWDV, 2019-06-19 reuters.com (Jo Johnston/Pixabay) Activist investor Alex Denner is back at it in biopharma. Fintel® is a registered trademark. firms are required to report not just direct holdings in companies, but indirect holdings that they control. Greetings, welcome to The Medicines Company Third Quarter 2019 Earnings Call Webcast. The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings call. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Sarissa Capital Management was one of those rare activist hedge funds, which managed to beat the last year’s tough market environment, returning 15.5%. PFZ Fintel® is a registered trademark. UNH This compares to loss of $0.63 per share a year ago. Fintel currently tracks over 9500 funds and over 63,000 securities traded worldwide. BMN Fintel® provides advanced research tools for data-driven investors Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). PFZ PFIZER, 2019-06-19 zacks.com MDCO, 2019-10-09 malaymail.com - Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) along with partner Allergan (AGN - Free Report) announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). - TORONTO, June 20 — The S&P 500 approached a record high yesterday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. See our Privacy Policy and Terms and Conditions. ACT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. IRWD Scott A. Barshay is Chair of the Paul, Weiss Corporate Department. result in a cost basis of zero. Mr. Schoen has also represented numerous companies in defending against hedge fund activism. - The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings call. - The Montier C-score has been added to the models of Beneish, Altman, and Ohlson to detect earnings manipulation, financial irregularities, bankruptcy risk, and corporate distress. - The S&P 500 approached a record high on Wednesday after the Federal Reserve signaled potential interest cuts later this year, reassuring investors worried that the U.S.-China trade war could stall economic growth. Contact us, SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. His practice focuses on advising clients on mergers and acquisitions, activist defense and other significant corporate matters. PFE Fintel® provides advanced research tools for data-driven investors SRNE value of their activist positions at year-end 2018) each invested more than $1 billion in new campaigns in 2018.2 52% of all board seats won globally since 2013 have been won by a group of 11 activists (in order of board seats won): Starboard, Elliott, Icahn, JANA, Engaged Capital, Sarissa Capital, ValueAct, Corvex, FrontFour, Glenview and Legion The Schedule 13D reveals that Sarissa Capital Management has gobbled up 6.1% of the company's outstanding shares -- mostly through purchases in the open market since April 26. This website is provided “as is” without any representations or warranties, express or implied. : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file. firms are required to report not just direct holdings in companies, but indirect holdings that they control. - The S&P 500 approached a record high on Wednesday after the Federal Reserve signalled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. IRWD Sarissa Capital Management LP closes activist position in MDCO / Medicines Company. Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue. [Operator Instructions] Please note this conference is being recorded. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. The Security, Class, and ID columns in the table below are shown exactly as filed by the investor. This represents 0.0 percent ownership of the company. that to calculate gross profit. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. Sarissa Capital Management intends to nominate Alex Denner for Ironwood's board. FIXX Backtesting this small cap activist strategy back to 2001 shows equally impressive performance — a 21.6% annualized return and a cumulative return of 2705%. Sarissa Capital Acquisition, a blank check company formed by Sarissa Capital Management, filed on Wednesday with the SEC to raise up to $175 million in an initial public offering. IRWDV Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Note that the share values in this table (For a live blog on the U.S. stock market, click or type LIVE/ in a news window). - SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. In 2013 Denner founded Sarissa Capital Management LP located in Greenwich Connecticut, an investment fund, to capitalize on the compelling opportunities for positive shareholder activism created by the unique dynamics of the … Ironwood Pharmaceuticals, headquartered in Cambridge, Mass., and Allergan, headquartered in Dublin, Ireland, announced positive topline data from their Phase IIIb clinical trial of Linzess (linaclotide) in irritable bowel syndrome. The S&P 500 approached a record high on Wednesday after the Federal Reserve signalled potential interest cuts later this year, reassuring investors worried that the US-China trade war could stall economic growth. Scott also regularly counsels corporations and their directors on securities law, corporate governance, crisis management and internal investigations. Sarissa Capital Management. We do our best to track continuity of investments through acquisitions, and this will be reflected in - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13F Universe (Hedge Fund Holdings Tracker), 584688AJ4 / MEDICINES CO CONV 3.5% 01/15/2024 - 0.035% 2024-01-15, 584688AH8 / MEDICINES CO CONV 3.5% 01/15/2024 144A - 0.035% 2024-01-15, 584688AC9 / Medicines Company 1.375% Bond due 2017-06-01, 584688AE5 / Medicines Company 2.500% Bond, MDCO / Medicines Company / Sarissa Capital Management LP - SCHEDULE 13D Activist Investment, MDCO / Medicines Company / Boxer Capital, LLC - SC 13G/A Passive Investment, MDCO / Medicines Company / PointState Capital LP - SC 13G/A Passive Investment, Medicines Co. shares jump 17% in premarket after report of potential Novartis offer, Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha, The Medicines Company (MDCO) CEO Mark Timney on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha, GSK recalls popular heartburn drug Zantac globally after cancer scare, Winning Bounce/Lag Momentum Stocks For Week 41 Of 2019--10/7-10/11 | Seeking Alpha, Forensic Stock Analysis: The Highest Positive And Negative Scoring Stocks For October | Seeking Alpha, The Medicines Co. reiterated as Top Pick for 2019 at Chardan after positive results for cholesterol treatment, Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates. Sarissa Capital Management is raising money … is shown over time. For investment firms, these Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently Sarissa Capital Management LP, the activist hedge fund run by Alexander Denner that invests in pharmaceutical and healthcare companies, has hired asset management veteran Eric Vincent as … The Security, Class, and ID columns in the table below are shown exactly as filed by the investor. : 7)* Name of issuer: Ironwood Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 46333X108 Date of Event Which Requires Filing of this Statement: May 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is file, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. IMPHO 3)* THE MEDICINES COMPANY (Name of Issuer) Common Stock, par value $ $0.001 per share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use Webinars are open Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently Other investors with positions similar to Sarissa Capital Management LP include Behind the Scenes: Sarissa is an activist focused on health care. shares of Medicines Company (US:MDCO). All rights reserved. [Operator Instructions] Please be advised that this call is being taped at the company’s request. We do our best to track continuity of investments through acquisitions, and this will be reflected in MDCO, 2019-10-31 seekingalpha.com Sarissa Capital on Monday, March 13, named three individuals with extensive healthcare and and boardroom experience to a slate of independent directors the activist … - WASHINGTON, Oct 9 — GlaxoSmithKline yesterday said it is recalling the popular heartburn medicine Zantac in all markets as a “precaution,” days after the US Food and Drug Administration found “unacceptable” levels of probable cancer-causing impurity in the drug. Quarterly return is Gross Profit / Starting Portfolio value. - Medicines Co. (MDCO - Free Report) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.66. Shares have added about 6.9% in that time frame, outperforming the S&P 500. - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. for registration and will fill up soon, so sign up now! The WhaleWisdom activist small cap strategy showed a total return of 894.2% since 2009 — 3.49X the S&P 500 total return. AGN Need help or want to help improve Fintel? PFE UNH GREENWICH, Conn., Oct. 20, 2020 /PRNewswire/ -- Sarissa Capital Acquisition Corp. (the "Company") today announced the pricing of its initial public offering of 17,500,000 units, at a … When a company makes a change in a quarterly filing, it's almost always significant (or they wouldn't change it). Shares have added about 17.1% in that time frame, outperforming the S&P 500. WCH indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. 1)* The Medicines Company (Name of Issuer) Common Stock, $.001 Par Value Per Share (Title of Class of Securities) 584688105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru.